GLENMARK PHARMACEUTICALS
|
The Current P/E Ratio of GLENMARK PHARMACEUTICALS is -41.95.
Share Price | ₹1,477.0 | Jan 15,2025 |
Market Cap | ₹41,680.9 Cr | |
Earnings-TTM | ₹-993.5 Cr | TTM-Consolidated Results |
Price/Earnings | -41.95x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹41,680.9 Cr] as on Jan 15,2025
(/) Earnings [ ₹-993.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -41.95x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay -41.95 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLENMARK PHARMACEUTICALS
PE Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 15.68x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 13.25x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2023 at 44.14x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does GLENMARK PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
GLENMARK PHARMACEUTICALS | -993.50 | -41.95 | 41,680.9 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 37.85 | 421,527.0 |
CIPLA LTD | 4,485.22 | 26.05 | 116,854.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 20.67 | 111,746.0 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 23.05 | 99,093.9 |
DIVIS LABORATORIES LTD | 1,836.00 | 84.99 | 156,037.0 |
MANKIND PHARMA LTD | 2,124.86 | 50.39 | 107,078.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 60.37 | 108,781.0 |
LUPIN LTD | 2,651.94 | 36.61 | 97,093.5 |
AUROBINDO PHARMA LTD | 3,598.83 | 18.52 | 66,638.3 |
ABBOTT INDIA LTD | 1,284.66 | 45.92 | 58,996.5 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK PHARMACEUTICALS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | -41.95x |
Max industry PE | 84.99x |
Median industry PE | 36.61x |
Average industry PE | 32.95x |
You may also like the below Video Courses